Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Inside Prince Andrew's 30Black cab driver who fled a fatal midnight hitOne year on, a lowJimenez homers to back Crochet as White Sox beat Cardinals 5Larson edges Buescher at the line at Kansas Speedway in closest finish in NASCAR Cup Series historyStock market today: Asian shares track Wall St's advance fueled by cooler jobs dataPanthers, Bruins set to meet again in playoff rematch, this time in Round 2A truck driver is accused of killing a Utah police officer by driving into himUK's ruling Conservative Party suffers heavy losses in local electionsMore misery as the UK's tax burden is set to hit an 80
3.164s , 6498.7265625 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,World Wave news portal